| pubmed-article:1721248 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0025936 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0024202 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0524637 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:1721248 | lifeskim:mentions | umls-concept:C0599796 | lld:lifeskim |
| pubmed-article:1721248 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1721248 | pubmed:dateCreated | 1992-1-23 | lld:pubmed |
| pubmed-article:1721248 | pubmed:abstractText | In order to characterize primary anti-HLA cytotoxic T cells and especially those involved in graft rejection, we have utilized a transgenic mouse model. Mice (non-transgenic and HLA-transgenic) were grafted with spleen cells originating from H-2-matched transgenic mice expressing HLA-B27 molecules, and cells from graft-draining lymph nodes were tested in CML assay to investigate the primary in vivo induced CTL responses. The results showed that HLA-B27 molecules were able to raise strong primary xenogeneic CTL responses. Results from split-well analysis indicated that although recognition of HLA-B27 by primary CTL induced in nontransgenic recipients is predominantly unrestricted by H-2, a small fraction (ranging from 2% to 27%) of the primary in vivo induced CTL is able to recognize HLA-B27 in an H-2-restricted manner. HLA-specific H-2-restricted CTL had never so far been demonstrated in the primary T cell response. Thus the protocol used in our study for the generation of a primary CTL response seems to provide not only a more appropriate representation of cytotoxic T cells sensitized by a graft, but also to be a more sensitive approach than the usually used in vitro mixed lymphocyte culture. | lld:pubmed |
| pubmed-article:1721248 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1721248 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1721248 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1721248 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1721248 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1721248 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1721248 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1721248 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:1721248 | pubmed:issn | 0041-1337 | lld:pubmed |
| pubmed-article:1721248 | pubmed:author | pubmed-author:DegosLL | lld:pubmed |
| pubmed-article:1721248 | pubmed:author | pubmed-author:PlaMM | lld:pubmed |
| pubmed-article:1721248 | pubmed:author | pubmed-author:RoccaAA | lld:pubmed |
| pubmed-article:1721248 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1721248 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:1721248 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1721248 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1721248 | pubmed:pagination | 1062-7 | lld:pubmed |
| pubmed-article:1721248 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:meshHeading | pubmed-meshheading:1721248-... | lld:pubmed |
| pubmed-article:1721248 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1721248 | pubmed:articleTitle | Analysis of primary HLA-specific cytotoxic T cell response in graft-draining lymph nodes--a transgenic mouse model for in vivo recognition of human MHC antigens. | lld:pubmed |
| pubmed-article:1721248 | pubmed:affiliation | U93 INSERM, Saint-Louis Hospital, Paris, France. | lld:pubmed |
| pubmed-article:1721248 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1721248 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
